A Tumor-Agnostic NTRK (TRK) Inhibitor.

Huang, Franklin W; Feng, Felix Y

Huang, Franklin W; Feng, Felix Y.

Affiliation

Huang FW; University of California, San Francisco, San Francisco, CA 94158.
Feng FY; University of California, San Francisco, San Francisco, CA 94158. Electronic address: felix.feng@ucsf.edu.

Cell ; 177(1): 8, 2019 03 21.

Article in En | MEDLINE | ID: mdl-30901551

ABSTRACT

ABSTRACT

Larotrectinib is a small-molecule kinase inhibitor that targets NTRK fusions that occur in multiple types of cancer. Its FDA approval represents the first instance of a treatment indication being designated "tumor-agnostic" from the outset, being based on actionable genomic insights. To view this Bench to Bedside, open or download the PDF.

Subject(s)

Pyrazoles/metabolism; Pyrazoles/pharmacology; Pyrimidines/metabolism; Pyrimidines/pharmacology; Receptor Tyrosine Kinase-like Orphan Receptors/metabolism; Humans; Neoplasms/genetics; Oncogene Proteins, Fusion/genetics; Protein Kinase Inhibitors/metabolism; Receptor Protein-Tyrosine Kinases/metabolism; Receptor Tyrosine Kinase-like Orphan Receptors/agonists; Receptor, trkB/metabolism

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Pyrazoles / Pyrimidines / Receptor Tyrosine Kinase-like Orphan Receptors Limits: Humans Language: En Journal: Cell Year: 2019 Type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google